nat2 polymorphism
Recently Published Documents


TOTAL DOCUMENTS

29
(FIVE YEARS 6)

H-INDEX

10
(FIVE YEARS 0)

Medicina ◽  
2021 ◽  
Vol 57 (10) ◽  
pp. 1095
Author(s):  
Hady Mohammadi ◽  
Mehrnoush Momeni Roochi ◽  
Masoud Sadeghi ◽  
Ata Garajei ◽  
Hosein Heidar ◽  
...  

Background and objective: N-acetyltransferases 1 and 2 (NAT1 and NAT2) genes have polymorphisms in accordance with slow and rapid acetylator phenotypes with a role in the development of head and neck cancers (HNCs). Herein, we aimed to evaluate the association of NAT1 and NAT2 polymorphisms with susceptibility to HNCs in an updated meta-analysis. Materials and methods: A search was comprehensively performed in four databases (Web of Science, Scopus, PubMed/Medline, and Cochrane Library until 8 July 2021). The effect sizes, odds ratio (OR) along with 95% confidence interval (CI) were computed. Trial sequential analysis (TSA), publication bias and sensitivity analysis were conducted. Results: Twenty-eight articles including eight studies reporting NAT1 polymorphism and twenty-five studies reporting NAT2 polymorphism were involved in the meta-analysis. The results showed that individuals with slow acetylators of NAT2 polymorphism are at higher risk for HNC OR: 1.22 (95% CI: 1.02, 1.46; p = 0.03). On subgroup analysis, ethnicity, control source, and genotyping methods were found to be significant factors in the association of NAT2 polymorphism with the HNC risk. TSA identified that the amount of information was not large enough and that more studies are needed to establish associations. Conclusions: Slow acetylators in NAT2 polymorphism were related to a high risk of HNC. However, there was no relationship between NAT1 polymorphism and the risk of HNC.


Author(s):  
Nur Farhana Mohamed Noor ◽  
Teh Lay Kek ◽  
Mohd Arif Mohd Zim ◽  
Zamzurina Abu Bakar ◽  
Noor Izyani Zakaria ◽  
...  

Background: N-acetyltransferase (NAT2) polymorphisms were reported to play important roles in antituberculosis-induced hepatotoxicity (ATDIH). However, the allelic types with increased risks for ATDIH were inconsistent as most studies are of a small sample size. Objective: The objective of the study was to conduct a meta-analysis to identify NAT2 alleles associated with increased risks of ATDIH. Methods: Studies reported on NAT2 polymorphism with the risk of ATDIH were searched systematically in PubMed, Scopus, and the World of Sciences. Studies were included if they fulfilled the inclusion criteria and excluded accordingly. Quality assessments were done using Newcastle-Ottawa Score. Statistical analysis was performed using Review Manager version 5.3. Cochrane Q-statistic test and I2 statistic were used to assess and quantify heterogeneity. Results: A total of 12 studies involving 580 cases and 3129 controls were included. NAT2 polymorphism was significantly associated with the risk of ATDIH with an odd ratio (OR) of 2.76 (1.86 – 4.10, 95% CI). Among the slow acetylators genotypes, NAT2*5/*7 carry the highest risk associated with ATDIH. Conclusion: NAT2 polymorphism was significantly associated with ATDIH.


2021 ◽  
Vol 11 ◽  
Author(s):  
Ke Zhu ◽  
Aiqun Xu ◽  
Wanli Xia ◽  
Pulin Li ◽  
Binbin Zhang ◽  
...  

Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. We researched 18 published studies, involving 4,016 patients and 5,469 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Our study was prospectively registered in PROSPERO (CRD42020159737). The odds ratio was 1.53 (95% CI: 1.21–1.95, I² = 45.2%, P=0.104) for the NAT2 slow + intermediate phenotype versus rapid phenotype. The results suggested that people with NAT2 non-rapid (slow + intermediate) phenotype have a significantly increased risk of lung cancer. In addition, NAT2 rapid phenotype was significantly associated with reduced risk of lung cancer, compared with slow phenotype or intermediate phenotype (slow phenotype vs. rapid phenotype: OR: 1.61, 95% CI: 1.07–2.42, I²= 50%, P= 0.075; intermediate phenotype vs. rapid phenotype: OR: 1.47, 95% CI: 1.15–1.88, I²= 40.3%, P= 0.137).


2020 ◽  
Author(s):  
Ke Zhu ◽  
Aiqun Xu ◽  
Binbin Zhang ◽  
Pulin Li ◽  
Huihui Jiang ◽  
...  

Abstract Background Lung cancer is the most common cancer in the world, and cancer death is mainly caused by lung cancer. At present, the etiology and pathogenesis of lung cancer are not clear. N-acetyltransferase 2 (NAT2) is an enzyme found in the lungs, colon, breast, prostate, and liver. NAT2 is polymorphic and can metabolize carcinogens from tobacco smoke. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. Methods We conducted a research of 19 published studies, involving 4,130 patients and 6,057 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Results From the major results, we found that there was no significant correlation between NAT2 polymorphism and lung cancer (OR = 1.00, 95% CI: 0.84–1.19, I² = 63.3%, P < 0.001 for heterogeneity). We also found no significant results in stratified analyses of smoking, ethnicity, gender, and source of controls. However, we learned from the subgroup analysis that the lung cancer risk in NAT2 patients with intermediate-slow acetylation may be increased (OR = 1.83, 95% CI: 1.22–2.73, I² = 39.6%, P = 0.191 for heterogeneity). Conclusions This research showed that no sufficient evidence was found to prove the effect of NAT2 polymorphism on lung cancer risk; however the increased acetylation capacity of NAT2 might reduce the risk of lung cancer.


Author(s):  
Pham Thi Hong Nhung ◽  
Kieu Hong Nhung ◽  
Dinh Doan Long ◽  
Vu Thi Thom ◽  
Le Thi Luyen ◽  
...  

The metabolism of Isoniazid, one of the first-line antituberculosis drugs for TB treatment and prophylaxis, depends on the acetyltransferase 2 acetylation (NAT2) phenotype. Different phenotypes of NAT2 will lead to differences in drug concentration and the risk of uncontrolled side effects, such as hepatitis, peripheral neuropathy, gastrointestinal disorders (nausea, vomiting, and stomach pain). These risks are related to the presence of mutant NAT2 alleles such as NAT2*5 (c.341T> C), *6 (c.590G> A) and *7 (c.857G> A), that reduce the N- acetyltransferase activity. Therefore, the genotyping method for NAT2 polymorphism using RFLP and Sanger sequencing was established. The method was successfully applied to determine the polymorphism of 84 TB patients. This study provides a better tool for analyzing NAT2 gene to assist clinicians in treating isoniazid. Keywords Enzyme NAT2, isoniazid, single nucleotide polymorphism, RFLP, Sanger sequencing. References [1] U.A. Boelsterli, K.K. Lee, Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress, J. Gastroenterol. Hepatol. 29 (2014) 678–687.[2] A. Zabost, S. Brzezinska, M. Kozinska, M. Blachnio, J. Jagodzinski, Z. Zwolska, E. Augustynowicz-Kopec, Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients, Biomed Res Int. 2013 (2013) 1-5.[3] M. Kinzig-Schippers, D. Tomalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, M. Rodamer, I. Cascorbi, O. Doroshyenko, F. Sorgel, U. Fuhr, Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 49 (2005) 1733-8[4] K. Walker, G. Ginsberg, D. Hattis, D.O. Johns, K.Z. Guyton, B. Sonawane, Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity, J Toxicol Environ Health B Crit Rev. 12 (2009) 440-472. [5] G. Ramachandran, S. Swaminathan, Role of pharmacogenomics in the treatment of tuberculosis: a review, Pharmgenomics Pers Med. 5 (2012) 89-98.[6] J. Azuma, M. Ohno, R. Kubota, S. Yokota, T. Nagai, K. Tsuyuguchi, Y. Okuda, T. Takashima, S. Kamimura, Y. Fujio, I. Kawase, Pharmacogenetics-based tuberculosis therapy research group, NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy, Eur J Clin Pharmacol. 69 (2013) 1091-1101.[7] P.S. Adole, P.S. Kharbanda, S. Sharma, N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study, Indian J Med Res. 143 (2016) 581-590.[8] WHO Scientific Group on Pharmacogenetics and World Health Organization, Pharmacogenetics: report of a WHO scientific group,World Health Organization Technical Report Series. (1973)[9] T.D. Da Silva, A.V. Felipe, J.M. De Lima, C.T. Oshima, N.M. Forones, N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer, World J Gastroenterol. 17 (2011) 760-765. [10] E.Y. Lau, J.S. Felton, F.C. Lightstone, Insights into the o-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: a computational study, Chem Res Toxicol. 19 (2006) 182-1190.[11] Ensembl - EBI, http://asia.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=8:18399844-18400844;v=rs1801280;vdb=variation;vf=1243314,2019 (Ensembl release 96 - April 2019).[12] I.B. Kuznetsov, M. McDuffie, R. Moslehi, A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype, Bioinformatics. 25 (2009) 1185-1186. [13] P. Wang, K. Pradhan, X.B. Zhong, X. Ma, Isoniazid metabolism and hepatotoxicity, Acta Pharm Sin B. 6 (2016) 384-392.[14] M. Ohno, I. Yamaguchi, I. Yamamoto, T. Fukuda, S. Yokota, Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity, Int J Tuberc Lung Dis. 4 (2000) 256-261. [15] G.M. Lower, T. Nilsson, C.E. Nelson, H. Wolf, T.E. Gamsky, G.T. Bryan, N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark, Int J Epidemiol. 36 (2007) 11-18.      


Breast Cancer ◽  
2017 ◽  
Vol 25 (2) ◽  
pp. 176-184 ◽  
Author(s):  
Z. Regev-Avraham ◽  
O. Baron-Epel ◽  
S. K. Hammond ◽  
L. Keinan-Boker

Oncotarget ◽  
2017 ◽  
Vol 8 (34) ◽  
pp. 57440-57450 ◽  
Author(s):  
Feng Wang ◽  
Zhiqiang Qin ◽  
Shuhui Si ◽  
Jingyuan Tang ◽  
Lingyan Xu ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 2569-2569
Author(s):  
Francis Levi ◽  
Raphael Saffroy ◽  
Abdoulaye Karaboue ◽  
Christophe Desterke ◽  
Valerie Boige ◽  
...  

2569 Background: The HAI of Irinotecan-Oxaliplatin-5-Fluorouracil (IFO) with IV-Cet achieved 29.7% complete uLM-CRC resections (R0+R1) and an overall median survival (OS) of 25.7 months in previously treated pts (Lévi, Ann Oncol 2016). Methods: To identify pharmacogenomic predictors of outcomes, 207 single nucleotide polymorphisms (SNPs) from 34 pharmacology genes were analysed in blood mononuclear cells (ADME PGx, MassArray platform, Sequenom, USA). Relations between SNPs and tumor response, R0+R1, survival, and toxicities were tested using adjusted Mann Whitney, Fisher Exact, Log Rank tests and Hardy-Weinberg Equilibrium. Results: Pts (16F;36M; 33-76 yo; WHO performance status 0-1) received protocol treatment as 2nd (21 pts) or 3-4thline (31 pts). VKORC1 SNPs in promoter (rs9923231) and intron (rs9934438) were consistently associated with early and objective responses, and overall survival. For rs9923231, T/T (N = 8) as compared to C/T (N = 21) had greatest chance of achieving early response (50% vs 5%, p = 0.029) or 4-y survival (46% vs 0%, p = 0.006). VKORC1 SNPs also related to HA thrombosis (rs992331, T/T, 77% vs C/C, 30%, p = 0.04). In contrast, NAT2 SNPs (rs1041983 and rs1801280) were associated with up to 5-fold differences in R0-R1 resection rate. Statistically significant associations (p < 0.05) of SNPs with clinical outcomes were found for oxydo-reduction (CYP2E1 and HA thrombosis; CYP2C9 and diarrhea; CYP2C19 and diarrhea, fatigue, and early response), conjugation (UGT1A1 and diarrhea; NAT2 and fatigue); and transport (ABCB1 or SLC0B3 and neutropenia; SLC22A1 and diarrhea; SLC 15A2 and early response). Conclusions: VKORC1 was highlighted for the first time, as a pharmacogenomic predictor of HAI efficacy for LM-CRC. Conversion-to-resection was associated with NAT2 polymorphism. VKORC1 γ-carboxylates vitamin K-dependent proteins. Its polymorphism guides personalized warfarin dosing. VKORC1 SNPs determination could help identify the uLM-CRC pts who best benefit from intensive HAI therapy. Clinical trial information: NCT00852228.


2017 ◽  
Vol 26 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Retno W. Susilowati ◽  
Kinasih Prayuni ◽  
Intan Razari ◽  
Syukrini Bahri ◽  
Rika Yuliwulandari

Background: Arylamine N-acetyltransferase 2 (NAT2) polymorphism was previously reported to have association with the risk of drug toxicities and the development of various diseases. Previous research on the Indonesian population, especially Javanese and Sundanese, showed that there were 33% NAT2 slow acetylator phenotype. The aim of this study was to map the NAT2 variation in the Malay ethnic to gain a deeper insight into NAT2 haplotypic composition in this ethnic.Methods: 50 healthy samples from the Indonesian Malay ethnic were obtained. They were interviewed about their ethnic backgrounds for the last three generations. DNA was extracted from peripheral blood and NAT2 genotyping was done using the PCR direct Sequencing. Data were compiled according to the genotype and allele frequencies estimated from the observed numbers of each specific allele. Haplotype reconstruction was performed using PHASE v2.1.1 software.Results: We found 7 haplotypes consisting of 6 SNPs and 14 NAT2 genotype variations in Indonesian Malay population. The most frequent allele was NAT2*6A (38%) which was classified as a slow acetylator allele. According to bimodal distribution, the predicted phenotype of the Malay population was composed of 62% rapid acetylator and 38% slow acetylator. According to trimodal distribution, the predicted phenotypes for rapid, intermediate and slow acetylators were 10%, 52% and 38% respectively.Conclusion: Our result indicates the presence of the allelic distribution and revealed the most frequent acetylator status and phenotype for the Indonesian Malay population. The result of this study will be helpful for future epidemiological or clinical studies and for understanding the genetic basis of acetylation polymorphism in Indonesia.


Sign in / Sign up

Export Citation Format

Share Document